Priti S. Hegde
Foundation Medicine (United States) · 263 works · 33,328 citations · h-index 51
Top works
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- A Concise Guide to cDNA Microarray Analysis
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- Top 10 Challenges in Cancer Immunotherapy
- Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
- The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
- Identification of tumor markers in models of human colorectal cancer using a 19,200-element complementary DNA microarray.
- A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer
- The African trypanosome genome
- Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC).
- Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
- OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients
- Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade